Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Trial of PCSK9 Inhibition in Patients with Acute Stroke and Symptomatic Intracranial Atherosclerosis - a Prospective, Randomized, Open-label, Blinded End-point Study with High-resolution MR Vessel Wall Imaging

NCT05001984 is registered in ClinicalTrials.gov with Chang Gung Memorial Hospital as lead sponsor.

NCT NCT05001984
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05001984 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Trial of PCSK9 Inhibition in Patients with Acute Stroke and Symptomatic Intracranial Atherosclerosis - a Prospective, Randomized, Open-label, Blinded End-point Study with High-resolution MR Vessel Wall Imaging
Lead sponsor
Chang Gung Memorial Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 1, 2021
Completion date
April 15, 2025
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke, icas - intracranial atherosclerosis, intracranial atherosclerosis